Biotech | February 18, 2022
USFDA clears Kairos Pharma’s IND to treat prostrate cancer
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
The partnership will help digitize and automate existing tasks traditionally managed on paper, significantly reducing costs and lead times while increasing compliance
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
Resolv ER may remedy leading causes of blindness in adults
Gupta to retire at the end of his current term on May 12, 2022, after more than a decade of service, during which time Avantor has transformed into a global life sciences leader
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers
Funding to grow the insurance and digital therapeutics vertical in India
Subscribe To Our Newsletter & Stay Updated
